Title: Chairman of the Board
Company: Tosk, Inc.
Location: Mountain View, California and Sunnyvale, California, United States
Harold L. Crow, Chairman of the Board at Tosk, Inc., has been recognized by Marquis Who’s Who Top Executives for dedication, achievements, and leadership in the pharmaceutical industry.
After earning an Associate of Arts from the Los Angeles City College in 1961, Mr. Crow went on to achieve a Bachelor of Arts in humanities from San Francisco State University in 1964. He then spent the following two years in West Bengal, India as a volunteer with the Peace Corps, where he was recognized for the excellence of his work and asked to help assemble another group of volunteers for India. From 1966 to 1971, he served as country director of the Peace Corps, receiving Foreign Service Reserve status for five years in which he was sent to Colombia, Uruguay and Panama in two-year stints. Mr. Crow joined Family Planning International Assistance (FPIA) in 1971 where he helped to establish new family planning programs around the world, with funding from the United States Agency for International Development. He then served as director of international operations for Population Services International (PSI), where he was instrumental in initiating social markets to family planning efforts until 1977.
Mr. Crow’s work in family planning steered him to a career switch into the pharmaceutical industry. Recruited by the Alza Corporation to become director of international operations, a position he held from 1976 to 1978. Following Alza, he was recruited to join the Syntex Corporation, first working in corporate development, then transferring to Hong Kong where he served as Asia area director from 1982 to 1993. Simultaneously, in 1988, he attended and participated in a summer executive program in finance at the University of Pennsylvania’s Wharton School. Additionally, Mr. Crow served as vice president of Vesta Medical, Inc. from 1993 to 1996 as well as president and chief executive officer for Aquintel, Inc. from 1996 to 1998 and for Hystagel, Inc. from 1998 to 2000.
Upon leaving Syntex, Mr. Crow opted to focus on start-up medical companies in Silicon Valley accepting a position as vice president of Vesta Medical, Inc. from 1993 to 1996. Following Vesta Medical’s success, Mr. Crow, together with a partner, Dr. Thierry Vancaillie, started a new company, Aquintel, Inc. where he served as president and chief executive officer from 1996 to 1998. Then from 1998 to 2000, Mr. Crow was a principal in starting another company, Hystagel, Inc. which developed a novel means of measuring the amount of fluid lost into the body during gynecological procedures.
Another start-up company followed but did not succeed, then beginning in 2008, Mr. Crow was elected to serve as chairman of the board for Tosk, Inc, which discovers and develops new drugs to prevent the undesirable side effects of widely-used cancer therapies and to block the proteins produced by cancer genes that drive tumor growth. This technology is being deployed to discover drugs for indications that have previously been considered “undruggable.” Tosk’s first target for this technology is the mutant kRAS gene that drives as many as 30% of all cancers. In his role, he helps guide policies and programs to keep the company on track to achieving its mission.
Notably, Mr. Crow has been the recipient of a public speaking award and highly regarded for his professional and civic experiences. He is a former member of the Commonwealth Club and before his knees became a problem spent his free time golfing and running. Mr. Crow credits the multiple teachers who took him under his wing for his career success. His personal objective is to always be kind to others and to work for the good of all people.
Contact Mr. Crow: